<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402016000200157</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2015.09.007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Por qué es importante lograr metas de hipertensión arterial sistémica... A propósito un caso clínico que inició como evento vascular cerebral isquémico]]></article-title>
<article-title xml:lang="en"><![CDATA[Why is it important to achieve the goals of treatment of hypertension.... About a case that began as ischemic stroke]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sauza-Sosa]]></surname>
<given-names><![CDATA[Julio César]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romero-Figueroa]]></surname>
<given-names><![CDATA[José Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sierra-Galán]]></surname>
<given-names><![CDATA[Lilia Mercedes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferez-Santander]]></surname>
<given-names><![CDATA[Sergio Mario]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Centro Médico American British Cowdray  ]]></institution>
<addr-line><![CDATA[México D.F.]]></addr-line>
<country>México</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Centro Médico American British Cowdray  ]]></institution>
<addr-line><![CDATA[México D.F.]]></addr-line>
<country>México</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Centro Médico American British Cowdray  ]]></institution>
<addr-line><![CDATA[México D.F.]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2016</year>
</pub-date>
<volume>86</volume>
<numero>2</numero>
<fpage>157</fpage>
<lpage>162</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402016000200157&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402016000200157&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402016000200157&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La hipertensión arterial sistémica (HAS) es una de las condiciones más frecuentes que se ve en atención primaria de las enfermedades cardiovasculares y que tiene como consecuencias; dependiendo del "órgano blanco" que afecte, producir la cardiopatía isquémica, la vasculopatía cerebral o la nefropatía crónica. Dentro de la patogénesis de la HAS se encuentran implicados varios mecanismos fisiopatológicos; de los cuales actualmente, por señalar los más importantes y frecuentes, juegan un papel el incremento en los niveles de adrenalina, el sistema renina-angiotensina-aldosterona y en fecha reciente, mucho se menciona la participación de la resistencia a la insulina y la hiperinsulinemia. Dichos procesos conllevan un desequilibrio entre el tono simpático y el parasimpático, aunado a la hipersensibilidad por el sodio desencadenan uno de los mecanismos fisiopatogénicos de la HAS. Actualmente se define la HAS como el hallazgo de cifras de tensión arterial mayores a 140/90 mm Hg. Este es uno de los padecimientos que más afecta a la población mundial encontrando prevalencias en grupos etarios y de género de 45 al 55% en varones entre los 45 y 70 años y del 45 al 65% en mujeres de ese mismo grupo etario. En el 2013 se publicaron las guías clínicas más recientes para su tratamiento y las metas recomendadas, con lo que se ha logrado disminuir sus complicaciones y mortalidad; dentro de las que destacan enfermedades vasculares como la cardiopatía isquémica y la cerebral y renal. En el presente trabajo se comenta un caso clínico que ejemplifica las complicaciones secundarias en un diagnóstico tardío, el daño a "órgano blanco" por exposición a largo plazo y el inadecuado cumplimiento de las metas terapéuticas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Systemic arterial hypertension (SAH) is one of the most common conditions seen in primary care of cardiovascular disease and whose consequences; depending on the "target organ" affecting produce ischemic heart disease, cerebral vascular disease or chronic kidney disease. In the pathogenesis of HAS are several physiopathological mechanisms involved; of which currently, to name the most important and frequent play a role in increasing adrenaline levels, the renin-angiotensin-aldosterone system and recently, much the participation of insulin resistance and hyperinsulinemia mentioned. These processes lead to an imbalance between the sympathetic and parasympathetic tone, coupled with hypersensitivity sodium trigger one of the pathophysiologic mechanisms of hypertension. SAH is currently defined as finding numbers of older blood pressure 140/90 mm Hg. This is one of the diseases that most affect the world population prevalences found in age and gender groups 45 to 55% in men between 45 and 70 years and 45 to 65% in women of the same age group. In 2013 most recent clinical guidelines for treatment and the recommended goals, which has managed to reduce its complications and mortality were published; among which include vascular diseases such as ischemic heart and brain and kidney. In this paper a case that exemplifies the secondary complications in late diagnosis, damage to "target organ" by long-term exposure and inadequate compliance with therapeutic goals discussed.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hipertensión arterial]]></kwd>
<kwd lng="es"><![CDATA[Cardiopatía hipertensiva]]></kwd>
<kwd lng="es"><![CDATA[Fibrilación auricular]]></kwd>
<kwd lng="en"><![CDATA[Arterial hypertension]]></kwd>
<kwd lng="en"><![CDATA[Hypertensive heart disease]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Egan]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Axon]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>2010</year>
<volume>303</volume>
<page-range>2043-50</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[2014 Evidence-based guideline for the management of high blood pressure in adults Report from the panel members appointed to the eighth Joint National Committee (JNC 8)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Oparil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>2013</year>
<volume>1097</volume>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chobanian]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>2003</year>
<volume>289</volume>
<page-range>2560-72</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Blood 25-hydroxyvitamin D concentration and hypertension a meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burgaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Orsini]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Larsson]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<source><![CDATA[J. Hypertens]]></source>
<year>2011</year>
<volume>29</volume>
<page-range>636-45</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk factors for arterial hypertension in adults with initial optimal blood pressure the Strong Heart Study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Simone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Devereux]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Chinali]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Hypertension]]></source>
<year>2006</year>
<volume>47</volume>
<page-range>162-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence and interrelations of no communicable chronic disease and cardiovascular risk factors in Mexico]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velázquez-Monroy]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Rosas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2003</year>
<page-range>62-77</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kurella Tamura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yaffe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin. J. Am. Soc. Nephrol]]></source>
<year>2011</year>
<volume>6</volume>
<page-range>248-56</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis North American Symptomatic Carotid Endarterectomy Trial Collaborators. N. Engl]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inzitari]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Eliasziw]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gates]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[J. Med]]></source>
<year>2000</year>
<volume>342</volume>
<page-range>1693-700</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Left ventricular hypertrophy pathogenesis, detection, and prognosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lorell]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Carabello]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2000</year>
<volume>102</volume>
<page-range>470-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The natural history of congestive heart failure the Framingham study. N. Engl]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKee]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Castelli]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[McNamara]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[J. Med]]></source>
<year>1971</year>
<volume>285</volume>
<page-range>1441-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ESH/ESC 2007 Guidelines for the management of arterial hypertension]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Backer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dominiczak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev. Esp. Cardiol]]></source>
<year>2007</year>
<volume>60</volume>
<numero>968</numero>
<issue>968</issue>
<page-range>e1-e94</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Definitions, natural histories and consequences]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pickering]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hypertension]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Med]]></source>
<year>1972</year>
<volume>52</volume>
<page-range>570-83</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Autonomic and hemodynamic origins of pre-hypertension Central role of heredity. J. Am. Coll]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Naqshbandi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiol]]></source>
<year>2012</year>
<volume>59</volume>
<page-range>2206-16</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guías clínicas para la detección, prevención, diagnóstico y tratamiento de la hipertensión arterial sistémica en México 2008. Comité Institucionalde Expertos en Hipertensión Arterial Sistémica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pastelín]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas-Alarcón]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2008</year>
<volume>78</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>S2-9 a S2108</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Conversión del adolescente pre-hipertenso al adulto hipertenso]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez-Fernández]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Grau-Abalo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2012</year>
<volume>82</volume>
<page-range>112-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guías de práctica clínica para el manejo de la fibrilación auricular]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY.H]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2010</year>
<volume>63</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1483</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuster]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rydén]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Cannom]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
<volume>123</volume>
<page-range>e269-367</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation nationwide cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olesen]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ]]></source>
<year>2011</year>
<volume>342</volume>
<page-range>d124</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
